Technology ID
TAB-1827

A Novel Treatment for Malarial Infections

E-Numbers
E-202-2008-0
Lead Inventor
Desai, Sanjay (NIAID)
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
Lead IC
NIAID
ICs
NIAID
The inventions described herein are antimalarial small molecule inhibitors of the plasmodial surface anion channel (PSAC), an essential nutrient acquisition ion channel expressed on human erythrocytes infected with malaria parasites. These inhibitors were discovered by high-throughput screening of chemical libraries and analysis of their ability to kill malaria parasites in culture. Two separate classes of inhibitors were found to work synergistically in combination against PSAC and killed malaria cultures at markedly lower concentrations than separately. These inhibitors have high affinity and specificity for PSAC and have acceptable cytotoxicity profiles. Preliminary in vivo testing of these compounds in a mouse malaria model is currently ongoing.
Commercial Applications
  • Treatment of malarial infections
Competitive Advantages
  • Novel drug treatment for malarial infections
  • Synergistic effect of these compounds on PSAC
Licensing Contact: